Nippon India Pharma Fund Direct Growth
Equity
Direct
Sector - Healthcare
About the Fund
Nippon India Pharma Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.
Key Parameters
- Nippon India Pharma Fund Direct Growth has ₹7404 Cr worth of assets under management (AUM) as on Jun 2024 and is more than category average.
- The fund has an expense ratio 0.9.
Returns
Nippon India Pharma Fund Direct Growth has given a CAGR return of 18.98% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 43.61%, 15.59% and 28.80% respectively.
Holdings
Nippon India Pharma Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Lupin Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of Nippon India Pharma Fund Direct Growth
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Nippon India Pharma Fund Direct Growth has no lock in period.
Fund Performance
6718 people have invested ₹ 4.2Cr in Nippon India Pharma Fund Direct Growth in the last three months
INDmoney Rank
Powered by IND quant engine
IND ranking is not available for this fund.
Among most bought funds within the category
Larger AUM within category
Beats FD returns for both 3Y & 5Y duration
3Y returns in the bottom 25% of the category
Fund Overview
| Expense ratio | 0.92% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹7404 Cr |
| Inception Date | 1 January, 2013 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 1% |
| Lock In | No Lock-in |
TurnOver | 18.67% |
| Risk |   Very High Risk |
Fund Distributionas on (30-Jun-24)
Large cap
44.4%
Mid cap
34.6%
Small cap
19.4%
Sector Allocation
Health
100%
All changes are between Apr'24 and Jun'24
as on (30-Jun-24)
See all
Returns for the month of Jun
Top Growth Drivers | 1M Return |
|---|---|
 Dr Reddys Laboratories Ltd | 13.4% |
 Sun Pharmaceuticals Industries Ltd | 7.2% |
 Divis Laboratories Ltd | 0.2% |
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund Direct Growth, since 1 April 2005
Top funds managed
Kinjal Desai
Fund Manager of Nippon India Pharma Fund Direct Growth, since 25 May 2018
Top funds managed
Mutual Fund Insights
In the last 1 year, Quant Healthcare Fund Direct Growth has given 60.96% return, outperforming this fund by 17.35%.
Over the last 15 months, this fund has decreased expense ratio by 27.0% moving from 1.26 to 0.92.
This fund with AUM at ₹7404.21Cr is among the largest funds in the sector - healthcare category.
Over the last 1 month, this fund has experienced a 3.4% growth in AUM moving from 7.16K Cr to 7.40K Cr.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.92% which is lower than the category average expense ratio of 1.42%.
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 18.75% return, outperforming this fund by 3.16% per annum.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 31.51% return, outperforming this fund by 2.71% per annum.
Nippon India Pharma Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 18.98% since inception which is less than its category average return of 23.79%
Fund Allocations
This fund has an allocation of 99.44% in Equity, 0% in Debt and 0.56% in Cash related instruments
AUM size ₹7404 Cr
This fund has AUM of ₹7404 Cr which is more than its category average of ₹ 1743 Cr
Expense Ratio 0.92%
This fund has an expense ratio of 0.92% which is less than its category average expense ratio of 1.44%
Frequently Asked Questions
The current NAV of Nippon India Pharma Fund Direct Growth is ₹522.98 as on 25-Jul-2024.
Existing (Absolute + CAGR) as on 25-Jul-2024.
Nippon India Pharma Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 6.3% | 6.3% |
6 Month Returns | 15.1% | 15.1% |
1 Year Returns | 43.61% | 43.61% |
3 Years Returns | 54.45% | 15.59% |
5 Years Returns | 254.5% | 28.8% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.92% as on June 2024
₹7404 Cr as on June 2024
Sun Pharmaceuticals Industries Ltd(13.47%), Divi's Laboratories Ltd(8.39%), Lupin Ltd(7.67%), Cipla Ltd(6.2%), Dr Reddy's Laboratories Ltd(6.05%) as on June 2024
The alpha ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Nippon India Pharma Fund Direct Growth | 2.84 | 1.14 | 3.34 |
As on June 2024
The alpha for Nippon India Pharma Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Nippon India Pharma Fund Direct Growth | 0.84 | 0.91 | 0.92 |
As on June 2024
The Beta for Nippon India Pharma Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Nippon India Pharma Fund Direct Growth | 2.19 | 0.64 | 1.13 |
As on June 2024
The sharpe ratio for Nippon India Pharma Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Nippon India Pharma Fund Direct Growth | 13.5 | 14.29 | 18.18 |
As on June 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.06 as on June 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.17 as on June 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Kinjal Desai are the fund managers of Nippon India Pharma Fund Direct Growth
The Exit load of Nippon India Pharma Fund Direct Growth is 1%